Xeris Biopharma Holdings

XERS · NASDAQ

$11.13+$0.18 (+1.64%)TodayMarket closed · Oct 20, 7:34 PM ET

Prev close $10.95

XERS analyst rating

BuyConsensus of 5 analysts over the last 12 months. 80% rate it a buy.

Strong buy0
Buy4
Hold1
Underperform0
Sell0

12-month price target · 9 analysts

Average $12.53 (+12.6% upside)

Low: $8.08
Now: $11.13
High: $18.90

Upgrades and downgrades

The latest rating actions, newest first

XERS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barclays	Oct 6, 2026	Maintains	Overweight	$12.00 → $14.00	53%
Leerink Partners	Sep 10, 2026	Maintains	Outperform	$12.00 → $16.00	35%
Barclays	Aug 20, 2026	Maintains	Overweight	$9.00 → $12.00	53%
HC Wainwright & Co.	Mar 2, 2026	Maintains	Buy	$10.00	36%
HC Wainwright & Co.	Jan 9, 2026	Maintains	Buy	$10.00	36%
Barclays	Dec 9, 2025	Initiates	Overweight	$9.00	53%
Oppenheimer	Nov 7, 2025	Maintains	Outperform	$18.00	45%
HC Wainwright & Co.	Nov 7, 2025	Maintains	Buy	$10.00	36%
Piper Sandler	Nov 7, 2025	Maintains	Neutral	$6.00 → $8.00	68%
Oppenheimer	Oct 29, 2025	Maintains	Outperform	$8.00 → $18.00	45%

The case for and against

Updated Aug 28, 2025

Bull case

Xeris Biopharma Holdings Inc. has demonstrated significant growth in key product sales, with Recorlev revenues increasing by 131% year-over-year to $22.6 million in 4Q24, and Gvoke sales rising by 25% to $23.3 million during the same period. The company also reported a substantial increase in new prescriptions, with a 123% growth in new starts for its products in 4Q24 compared to the prior year, indicating a widening prescriber base. Furthermore, a moderate increase in operational expenditures, guided to rise by mid-to-high single digits, suggests a stronger operating leverage and potential for improved profitability moving forward.

Bear case

Xeris Biopharma Holdings Inc. reported a narrower net loss per share of ($0.03) in the fourth quarter, outperforming estimates, yet it faces significant challenges due to potential R&D and FDA setbacks and increasing competition from generic drug makers. While the company provided revenue guidance for 2025 that suggests growth, the anticipated range of $255-$275 million only marginally exceeds prior estimates and raises concerns about sustaining momentum. Additionally, with a GAAP net income loss of ($5.1 million) and pressures from new market entries, the fundamental outlook remains bleak despite some positive quarterly performance metrics.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.